RxDoctor Payments Data

Angela Tyus, NP

Nurse Practitioner · Bainbridge, GANPI 1174851745

Payments from drug & device makers

$6,231in general payments, 2019–2025

Across 336 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$961
  • Takeda Pharmaceuticals U.S.A., Inc.$312
  • AstraZeneca$310
  • Almatica Pharma LLC$296
  • Pfizer$296
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,13198%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,231 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$3,487
Medicare patients
26
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide109$123,876
OzempicSemaglutide87$96,063
JardianceEmpagliflozin59$49,949
EliquisApixaban60$45,768
JanuviaSitagliptin Phosphate23$36,005
FarxigaDapagliflozin Propanediol46$31,646
VimpatLacosamide13$29,416
VraylarCariprazine Hcl16$23,381
LinzessLinaclotide25$18,821
MyrbetriqMirabegron21$9,329
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$8,107
DexilantDexlansoprazole19$6,936
Pitavastatin Calcium13$6,666
Memantine Hcl ErMemantine Hcl83$5,757
Dexlansoprazole DrDexlansoprazole20$4,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humulin 70-30$269$126,089136 claims
Novo NordiskOzempic$961$96,06387 claims
Boehringer IngelheimJardiance$140$49,94959 claims
PfizerEliquis$296$45,76860 claims
AbbVieVraylar, Linzess, Synthroid$1,314$43,56468 claims
MerckJanuvia$20$36,00523 claims
AstraZenecaFarxiga$310$31,64646 claims
Astellas Pharma US IncMyrbetriq$226$9,32921 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$312$6,93619 claims
Kowa Pharmaceuticals America, Inc.Livalo$118$3,42611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Bainbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →